Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism

• Published in: PloS one 2015-01, Vol.10 (1), p.e0116998-e0116998
• Main Authors: Olsen, Rachelle R, Mary-Sinclair, Michelle N, Yin, Zhirong, Freeman, Kevin W
• Format: Article
• Language: English
• Subjects: Addictions; Amino acids; Aniline Compounds - administration & dosage; Aniline Compounds - pharmacology; Animal models; Animals; Antagonists; Antimetabolites, Antineoplastic - administration & dosage; Antimetabolites, Antineoplastic - pharmacology; Apoptosis; Bax protein; Bcl-2 protein; Biotechnology; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Cancer; Cancer therapies; Carbon; Caspases - metabolism; Cell division; Cell Line, Tumor; Cell Proliferation - drug effects; Chemotherapy; Diazooxonorleucine - administration & dosage; Diazooxonorleucine - pharmacology; Drug Synergism; Ewings sarcoma; Families & family life; Fatty acids; Glutamine; Glutamine - antagonists & inhibitors; Health aspects; Humans; Inhibition; Medical prognosis; Metabolism; Mice; Myc protein; Neuroblastoma; Neuroblastoma - drug therapy; Neuroblastoma - metabolism; Norleucine; Oncology; Pediatrics; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-myc - metabolism; Sarcoma; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - metabolism; Sulfonamides - administration & dosage; Sulfonamides - pharmacology; Synergistic effect; Tumors; Xenograft Model Antitumor Assays; Xenografts
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0116998

Neuroblastomas (NBL) and Ewing's sarcomas (EWS) together cause 18% of all pediatric cancer deaths. Though there is growing interest in targeting the dysregulated metabolism of cancer as a therapeutic strategy, this approach has not been fully examined in NBL and EWS. In this study, we first tested a panel of metabolic inhibitors and identified the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) as the most potent chemotherapeutic across all NBL and EWS cell lines tested. Myc, a master regulator of metabolism, is commonly overexpressed in both of these pediatric malignancies and recent studies have established that Myc causes cancer cells to become "addicted" to glutamine. We found DON strongly inhibited tumor growth of multiple tumor lines in mouse xenograft models. In vitro, inhibition of caspases partially reversed the effects of DON in high Myc expressing cell lines, but not in low Myc expressing lines. We further showed that induction of apoptosis by DON in Myc-overexpressing cancers is via the pro-apoptotic factor Bax. To relieve inhibition of Bax, we tested DON in combination with the Bcl-2 family antagonist navitoclax (ABT-263). In vitro, this combination caused an increase in DON activity across the entire panel of cell lines tested, with synergistic effects in two of the N-Myc amplified neuroblastoma cell lines. Our study supports targeting glutamine metabolism to treat Myc overexpressing cancers, such as NBL and EWS, particularly in combination with Bcl-2 family antagonists.